1. Home
  2. GEO vs MESO Comparison

GEO vs MESO Comparison

Compare GEO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geo Group Inc (The) REIT

GEO

Geo Group Inc (The) REIT

HOLD

Current Price

$15.43

Market Cap

2.2B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.11

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEO
MESO
Founded
1984
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
GEO
MESO
Price
$15.43
$16.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$41.00
$24.00
AVG Volume (30 Days)
1.7M
217.9K
Earning Date
02-12-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
515.49
N/A
EPS
1.69
N/A
Revenue
$2,531,574,000.00
$17,198,000.00
Revenue This Year
$7.93
$576.59
Revenue Next Year
$15.02
$41.15
P/E Ratio
$9.29
N/A
Revenue Growth
4.43
191.39
52 Week Low
$14.27
$9.61
52 Week High
$32.09
$21.50

Technical Indicators

Market Signals
Indicator
GEO
MESO
Relative Strength Index (RSI) 36.66 36.80
Support Level $15.42 $17.00
Resistance Level $16.57 $17.61
Average True Range (ATR) 0.71 0.60
MACD -0.24 -0.23
Stochastic Oscillator 3.85 2.40

Price Performance

Historical Comparison
GEO
MESO

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: